To Get Full Access :

Zurzuvae

Zurzuvae is a 14-day oral pill for adults with postpartum depression, offering rapid improvement in depressive symptoms. It helps new mothers regain mood balance after childbirth.

The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.

Molecule Details :

  • Molecule Name :

    Zuranolone
  • Innovator :

    BIOGEN INC
  • Approval Date :

    04-Aug-23
  • NCE-1 Date :

    04-Aug-27
  • NCE Date :

    04-Aug-28
  • Dosage Form :

    Capsule
  • Strength :

    20mg, 25mg and 30mg
  • Therapeutic Category :

    Antidepressant
  • Revenue ($M) :

    195

Year-wise Projected Sales ($M) :

  • 2026 :

    327
  • 2027 :

    435
  • 2028 :

    534
  • 2029 :

    614
  • 2030 :

    686
  • 2031 :

    749
  • 2032 :

    811
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

For full access Sign-up / Sign-in using below Methods:

By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.

Are you sure want to logout from NCE Grid?